FDA won't approve Bristol-Astra diabetes drug yet
TRENTON, N.J. (AP) — In a setback that could spell trouble for several drugmakers developing a new type of diabetes pill, U.S. regulators have told partners Bristol-Myers Squibb Co. and AstraZeneca PLC they can't approve its experimental drug without more data.
Shares of both companies fell more than 2 percent.
The Food and Drug Administration decision Thursday comes after expert FDA advisers in July reco...
You have selected to view an article that is older than 60 days. There are several ways to unlock access to NewsOK historical content.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
